Incyte Genomics Incy has had a mix of positive and negative outcomes recently. Encouraging
long-term data from their HS Studies and a display of a strong
momentum in their stock movements generated an increased buyer interest. Their stock was up by more than 7% in one week. In Q1, they beat their earnings estimate but missed their sales projection. Unfortunately, Q4 results did not meet earnings and revenue expectations. In another major development, Cathie Wood's ARK ETFs
sold some Incyte stock. Despite some fluctuations, their shares added an 8.3% value in a single session. They recorded an overall rise of 7% in a year, even though they were down by 29.6% year to date. Incyte has developed a strategic
partnership with Caris Life Sciences to boost its oncology pipeline. In regulatory news, their cholangiocarcinoma drug Pemazyre received EU approval.
Incyte Genomics INCY News Analytics from Thu, 05 Mar 2015 08:00:00 GMT to Sun, 26 May 2024 06:23:07 GMT -
Rating 5
- Innovation 2
- Information 6
- Rumor -4
